[ Arcturus Therapeutics raises $3M in Series B funding ]
Arcturus Therapeutics has raised $3 million in Series B funding.
Founded in 2013, Arcturus Therapeutics is focused on RNA medicines for the treatment of rare diseases. The company has developed a novel, potent and safe RNA Therapeutics platform called LUNARTM, a proprietary lipid-enabled delivery system for RNA medicines including small interfering RNA, messenger RNA, antisense, and microRNA oligotherapeutics.
The new funds will go to advance LUNAR-CF, a novel messenger RNA (mRNA) therapeutic formulated with Arcturus’ drug delivery technology. The effort will support discovery and development of mRNA therapeutics that aim to enable cells of CF patients to restore the function of their cystic fibrosis transmembrane conductance regulator, or CFTR, gene in their lungs.
|City||San Diego, CA|
|Founder / CEO||Joseph Payne|
|Investors||Cystic Fibrosis Foundation|